Shaun P Cordoba

This paper develops an in vivo CAR T cell platform using lipid nanoparticles and T-trex strategy to enhance safety, efficacy, and tumor control.

This paper develops a novel CAR-T cell therapy for glioblastoma that overcomes immunosuppression and improves persistence through a multi-armoured design.

The paper develops a small-molecule control system using minocycline to disrupt protein-protein interactions for reversible and dose-dependent control of therapeutic applications.

This study identifies Fas-CD40 as a chimeric Fas-TNFR that prevents Fas ligand-mediated kill and enhances CAR T-cell efficacy through synergistic signaling.